XBiotech Inc. carries no debt; cash flow comfortably covers obligations.

XBiotech Inc.'s free cash flow has decreased 24.61% from $-32.27M last year to $-40.21M, signaling decreasing performance

XBiotech Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

XBiotech Inc.'s debt has decreased relative to shareholder equity from 0.06 last year to 0.00 today, signaling strengthened financials

XBiotech Inc. has a net cash position, so leverage is healthy.

XBiotech Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

XBiotech Inc. has insufficient data to evaluate this check.

XBiotech Inc.'s short-term assets of $126.95M exceed its short-term liabilities of $7.93M

XBiotech Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

XBiotech Inc.'s return on equity of -26.10%, is lower than 15.00%, indicating bad performance

XBiotech Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

XBiotech Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

XBiotech Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

XBiotech Inc. has negative free cash flow, indicating cash burn

XBiotech Inc.'s yearly earnings has decreased 18.19% since last year from $-38.53M to $-45.54M, signaling decreasing performance

XBiotech Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -35.38% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

XBiotech Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

XBiotech Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

XBiotech Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

XBiotech Inc. has insufficient data to evaluate this check.

XBiotech Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

XBiotech Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

XBiotech Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

XBiotech Inc. has insufficient data to evaluate this check.

XBiotech Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

XBiotech Inc. has a price-to-book ratio of 0.51x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

XBiotech Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue